198 related articles for article (PubMed ID: 29720023)
1. Direct acting antiviral treatment of chronic hepatitis C in Denmark: factors associated with and barriers to treatment initiation.
Sølund C; Hallager S; Pedersen MS; Fahnøe U; Ernst A; Krarup HB; Røge BT; Christensen PB; Laursen AL; Gerstoft J; Bélard E; Madsen LG; Schønning K; Pedersen AG; Bukh J; Weis N;
Scand J Gastroenterol; 2018; 53(7):849-856. PubMed ID: 29720023
[TBL] [Abstract][Full Text] [Related]
2. Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals.
Prenner SB; VanWagner LB; Flamm SL; Salem R; Lewandowski RJ; Kulik L
J Hepatol; 2017 Jun; 66(6):1173-1181. PubMed ID: 28161470
[TBL] [Abstract][Full Text] [Related]
3. Barriers to treatment of chronic hepatitis C with direct acting antivirals in an urban clinic.
Malespin M; Harris C; Kanar O; Jackman K; Smotherman C; Johnston A; Ferm J; de Melo SW; Scolapio JS; Nelson DR; Cotler SJ
Ann Hepatol; 2019; 18(2):304-309. PubMed ID: 31053544
[TBL] [Abstract][Full Text] [Related]
4. Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis.
Maan R; van Tilborg M; Deterding K; Ramji A; van der Meer AJ; Wong F; Fung S; Sherman M; Manns MP; Cornberg M; Hansen BE; Wedemeyer H; Janssen HL; de Knegt RJ; Feld JJ
Clin Gastroenterol Hepatol; 2016 Dec; 14(12):1821-1830.e6. PubMed ID: 27404965
[TBL] [Abstract][Full Text] [Related]
5. Engagement in Care of High-Risk Hepatitis C Patients with Interferon-Free Direct-Acting Antiviral Therapies.
Dever JB; Ducom JH; Ma A; Nguyen J; Liu L; Herrin A; Groessl EJ; Ho SB
Dig Dis Sci; 2017 Jun; 62(6):1472-1479. PubMed ID: 28378246
[TBL] [Abstract][Full Text] [Related]
6. Identifying Barriers to the Treatment of Chronic Hepatitis C Infection.
Al-Khazraji A; Patel I; Saleh M; Ashraf A; Lieber J; Malik R
Dig Dis; 2020; 38(1):46-52. PubMed ID: 31422405
[TBL] [Abstract][Full Text] [Related]
7. Regression of liver fibrosis over a 24-week period after completing direct-acting antiviral therapy in patients with chronic hepatitis C receiving care within the national hepatitis C elimination program in Georgia: results of hepatology clinic HEPA experience.
Dolmazashvili E; Abutidze A; Chkhartishvili N; Karchava M; Sharvadze L; Tsertsvadze T
Eur J Gastroenterol Hepatol; 2017 Nov; 29(11):1223-1230. PubMed ID: 28857900
[TBL] [Abstract][Full Text] [Related]
8. The use of all-oral direct-acting antivirals in hepatitis C virus-infected patients with substance use disorders.
Jiang X; Song HJ; Wang W; Henry L; Childs-Kean LM; Re VL; Park H
J Manag Care Spec Pharm; 2021 Jul; 27(7):873-881. PubMed ID: 34185563
[No Abstract] [Full Text] [Related]
9. Safety of Direct-Acting Antiviral Therapy Regarding Renal Function in Post-Liver Transplant Patients Infected with Hepatitis C Virus and a 100% 12-Week Sustained Virologic Response-A Single-Center Study.
Peschel G; Moleda L; Baier L; Selgrad M; Schmid S; Scherer MN; Müller M; Weigand K
Transplant Proc; 2018 Jun; 50(5):1444-1450. PubMed ID: 29880368
[TBL] [Abstract][Full Text] [Related]
10. Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis-4 score and aspartate aminotransferase-platelet ratio index.
Bachofner JA; Valli PV; Kröger A; Bergamin I; Künzler P; Baserga A; Braun D; Seifert B; Moncsek A; Fehr J; Semela D; Magenta L; Müllhaupt B; Terziroli Beretta-Piccoli B; Mertens JC
Liver Int; 2017 Mar; 37(3):369-376. PubMed ID: 27678216
[TBL] [Abstract][Full Text] [Related]
11. Ineffective Absorption? Failure of Direct-Acting Therapy for Chronic Hepatitis C in Cirrhotic Patients With Roux-en-Y Gastric Bypass.
Tow CY; Reinus JF
J Investig Med High Impact Case Rep; 2019; 7():2324709619858127. PubMed ID: 31216918
[TBL] [Abstract][Full Text] [Related]
12. Predictors of early discontinuation of interferon-free direct antiviral agents in patients with hepatitis C virus and advanced liver fibrosis: results of a real-life cohort.
Miotto N; Mendes LC; Zanaga LP; Goncales ESL; Lazarini MSK; Pedro MN; Gonçales FL; Stucchi RSB; Vigani AG
Eur J Gastroenterol Hepatol; 2017 Oct; 29(10):1149-1154. PubMed ID: 28800033
[TBL] [Abstract][Full Text] [Related]
13. All-oral Direct-acting Antiviral Regimens in HIV/Hepatitis C Virus-coinfected Patients With Cirrhosis Are Efficient and Safe: Real-life Results From the Prospective ANRS CO13-HEPAVIH Cohort.
Sogni P; Gilbert C; Lacombe K; Piroth L; Rosenthal E; Miailhes P; Gervais A; Esterle L; Chas J; Poizot-Martin I; Dominguez S; Simon A; Morlat P; Neau D; Zucman D; Bouchaud O; Lascoux-Combe C; Bani-Sadr F; Alric L; Goujard C; Vittecoq D; Billaud E; Aumaître H; Boué F; Valantin MA; Dabis F; Salmon D; Wittkop L
Clin Infect Dis; 2016 Sep; 63(6):763-770. PubMed ID: 27317796
[TBL] [Abstract][Full Text] [Related]
14. Medication Non-adherence in a Prospective, Multi-center Cohort Treated with Hepatitis C Direct-Acting Antivirals.
Serper M; Evon DM; Stewart PW; Lok AS; Amador J; Reeve BB; Golin CE; Fried MW; Reddy KR; Sterling RK; Sarkar S; Di Bisceglie AM; Lim JK; Nelson DR; Reau N
J Gen Intern Med; 2020 Apr; 35(4):1011-1020. PubMed ID: 31659661
[TBL] [Abstract][Full Text] [Related]
15. Variation in hepatitis C virus treatment uptake between Canadian centres in the era of direct-acting antivirals.
Nitulescu R; Young J; Saeed S; Cooper C; Cox J; Martel-Laferriere V; Hull M; Walmsley S; Tyndall M; Wong A; Klein MB;
Int J Drug Policy; 2019 Mar; 65():41-49. PubMed ID: 30594080
[TBL] [Abstract][Full Text] [Related]
16. Population impact of direct-acting antiviral treatment on new presentations of hepatitis C-related decompensated cirrhosis: a national record-linkage study.
Hutchinson SJ; Valerio H; McDonald SA; Yeung A; Pollock K; Smith S; Barclay S; Dillon JF; Fox R; Bramley P; Fraser A; Kennedy N; Gunson RN; Templeton K; Innes H; McLeod A; Weir A; Hayes PC; Goldberg D
Gut; 2020 Dec; 69(12):2223-2231. PubMed ID: 32217640
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of direct-acting antiviral therapy for hepatitis C in difficult-to-treat patients in a safety-net health system: a retrospective cohort study.
Yek C; de la Flor C; Marshall J; Zoellner C; Thompson G; Quirk L; Mayorga C; Turner BJ; Singal AG; Jain MK
BMC Med; 2017 Nov; 15(1):204. PubMed ID: 29151365
[TBL] [Abstract][Full Text] [Related]
18. Delivering direct acting antiviral therapy for hepatitis C to highly marginalised and current drug injecting populations in a targeted primary health care setting.
Read P; Lothian R; Chronister K; Gilliver R; Kearley J; Dore GJ; van Beek I
Int J Drug Policy; 2017 Sep; 47():209-215. PubMed ID: 28587943
[TBL] [Abstract][Full Text] [Related]
19. Hepatocellular carcinoma risk assessment by the measurement of liver stiffness variations in HCV cirrhotics treated with direct acting antivirals.
Ravaioli F; Conti F; Brillanti S; Andreone P; Mazzella G; Buonfiglioli F; Serio I; Verrucchi G; Bacchi Reggiani ML; Colli A; Marasco G; Colecchia A; Festi D
Dig Liver Dis; 2018 Jun; 50(6):573-579. PubMed ID: 29567413
[TBL] [Abstract][Full Text] [Related]
20. Moderate Sustained Virologic Response Rates With 6-Week Combination Directly Acting Anti-Hepatitis C Virus Therapy in Patients With Advanced Liver Disease.
Kattakuzhy S; Wilson E; Sidharthan S; Sims Z; McLaughlin M; Price A; Silk R; Gross C; Akoth E; McManus M; Emmanuel B; Shrivastava S; Tang L; Nelson A; Teferi G; Chavez J; Lam B; Mo H; Osinusi A; Polis MA; Masur H; Kohli A; Kottilil S
Clin Infect Dis; 2016 Feb; 62(4):440-447. PubMed ID: 26503379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
